Clinical Trial Update: BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting phase 1/2 results for bemcentinib (BGB324) in combination with pembrolizumab or with dabrafenib/trametinib in metastatic melanom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BGB324 (bemcentinib) (bemcentinib)
• Dabrafenib (Dabrafenib)
• Pembrolizumab (pembrolizumab)
• Trametinib (trametinib)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED